Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01898195 · ClinicalTrials.gov registry record · NA
Improving Adherence to Smoking Cessation Medication Among PLWHA
A NA study of Tobacco Use Cessation, sponsored by NYU Langone Health.
- Completed
- Registry status
- NA
- Development phase
- 158
- Enrollment target
- 1
- Study location
NCT01898195 is a NA study of Tobacco Use Cessation that has completed, run by NYU Langone Health. The registered enrollment target is 158 participants, below the 880-participant average among 36 other Tobacco Use Cessation trials with a reported enrollment target (82% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01898195, a NA study of Tobacco Use Cessation, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- NA
- Development phase
- 158 participants
- Enrollment target
- 1
- Study location
Study Summary
Smoking rates among individuals living with HIV/AIDS range between 47% and 65%, a prevalence that is roughly three times the rate of the general population. This elevated prevalence is alarming given the increased likelihood of numerous adverse health outcomes experienced by HIV-positive smokers. Cigarette smoking is associated with greater levels of HIV-related symptom burden and appears to decrease the effectiveness of HAART as assessed by both viral load and CD4 counts (Vidrine 2009, Marshall 2009, Vidrine 2007, Miguez-Burbane 2005). PLWHA who smoke are also at increased risk of infections and noninfectious pulmonary complications and both AIDS-associated and non-AIDS-associated malignancies compared to nonsmokers. This study will refine and pilot test a theory-driven smoking cessation intervention that enhances existing behavioral approaches by testing the impact of text message reminders to take varenicline and the feasibility and additional impact of including adherence-focused behavioral cessation counseling. The investigators propose to randomize 190 participants, recruited from three HIV/AIDS clinic, to a three arm pilot study that compares: 1) Standard Care (SC), 2) SC + text message reminders, and 3) SC + text message reminders + cell phone-delivered adherence-focused behavioral therapy (ABT). Participants in all three arms will receive varenicline for 12 weeks. The primary outcomes are adherence to varenicline and biochemically validated smoking abstinence at 12 weeks and 3-month follow-up from the time of study enrollment.
Conditions Studied
Interventions
- DRUG Varenicline
- BEHAVIORAL Text Message
- BEHAVIORAL Adherence Behavioral Therapy
Study Locations (1)
New York
- Spencer Cox Center for Health - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 158 participants |
| Start Date | 2013-03 |
| Est. Completion | 2014-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01898195
The ClinicalTrials.gov registry entry for NCT01898195 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 158 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 880-participant average among 36 other Tobacco Use Cessation trials with a reported enrollment target (82% lower). The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Tobacco Use Cessation appearing as the primary indexed condition, and to 3 interventions - of which Varenicline is the first listed.
NCT01898195 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT01898195 about?
NCT01898195 is a clinical study titled "Improving Adherence to Smoking Cessation Medication Among PLWHA". Smoking rates among individuals living with HIV/AIDS range between 47% and 65%, a prevalence that is roughly three times the rate of the general population. This elevated prevalence is alarming given the increased likelihood of numerous adverse health outcomes experienced by HIV-positive smokers. Ci...
What is the current status of trial NCT01898195?
This trial is currently completed. It is a NA study. The enrollment target is 158 participants. The study started on 2013-03. Estimated completion is 2014-12.
What conditions does trial NCT01898195 study?
This clinical trial studies the following conditions: Tobacco Use Cessation.
What interventions are being tested in trial NCT01898195?
The interventions under investigation include: Varenicline (DRUG), Text Message (BEHAVIORAL), Adherence Behavioral Therapy (BEHAVIORAL).
Who is sponsoring clinical trial NCT01898195?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01898195 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Tobacco Use Cessation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Reach Through Equitable Implementation in Utah
RECRUITING · NA
-
Development of a Smoking Cessation Video Series
RECRUITING · NA
-
Trauma-Informed Care for Smoking Cessation for Pregnancy
RECRUITING · NA
-
Mi QUIT CARE (Mile Square QUIT Community-Access-Referral-Expansion)
RECRUITING · NA
-
Comprehensive Tobacco Cessation for Cancer Patients and Survivors
RECRUITING · NA
-
Comparative Effectiveness of Mobile Health Smoking Cessation Approaches Among Underserved Patients in Primary Care
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.